Multiple sclerosis following treatment with a cannabinoid receptor-1 antagonist

2004 ◽  
Vol 10 (3) ◽  
pp. 330-332 ◽  
Author(s):  
B W van Oosten ◽  
J Killestein ◽  
E MH Mathus-Vliegen ◽  
C H Polman
Keyword(s):  
Multiple Sclerosis ◽  
Animal Models ◽  
Receptor Antagonist ◽  
Human Disease ◽  
Cannabinoid Receptor ◽  
Therapeutic Potential ◽  
Laboratory Research ◽  
Cannabinoid Receptor 1 ◽  
Disease Pathogenesis

Laboratory research including animal models of human disease suggests that cannabinoids might have therapeutic potential in multiple sclerosis (MS). We have recently seen a 46-year-old woman who developed MS after starting treatment with a cannabino id recepto r antagonist for obesity. The occurrence of MS several months after starting a cannabinoid receptor antagonist suggests that the cannabino id system might indeed be relevant to disease pathogenesis in MS.

scholarly journals Cannabis as a Possible Treatment for Spasticity in Multiple Sclerosis / Kanabis Kao Moguci Tretman U Lecenju Spasticnosti Kod Multiple Skleroze

2016 ◽  
Vol 17 (1) ◽  
pp. 61-66
Author(s):  
Katarina Vesic ◽  
Slavica Djukic Dejanovic ◽  
Milica Borovcanin ◽  
Janko Samardzic ◽  
Gordana Toncev
Keyword(s):  
Multiple Sclerosis ◽  
Cannabinoid Receptor ◽  
Therapeutic Potential ◽  
Positive Impact ◽  
Moderate Intensity ◽  
Symptom Improvement ◽  
Clinical Environment ◽  
Cannabinoid Receptor 2 ◽  
Multiple Sclerosis Patients ◽  
Based Medicine

Abstract The therapeutic potential of cannabis has been known for centuries. Cannabinoids express their effects through two types of receptors, cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2). Present studies indicate that cannabis-based drugs can make a positive impact in the treatment of different diseases. For many years, multiple sclerosis patients have self-medicated with illegal street cannabis to alleviate spasticity, a common and debilitating symptom that impairs quality of life. Nabiximols is the cannabis-based medicine approved in many countries as an add-on therapy for symptom improvement in patients with spasticity who have not responded adequately to other medications. Adverse events such as dizziness, diarrhoea, fatigue, nausea, headache and somnolence occur quite frequently with nabiximols, but they are generally of mild-to-moderate intensity and their incidence can be markedly reduced by gradual uptitration. The prerequisite for the therapeutic use of cannabis in Serbia arerequires legal clarification for the use of the drug in a clinical environment

Cannabinoid Receptor 1: Allosteric Modulation and its Therapeutic Potential

2020 ◽  
Vol 9 (8) ◽  
pp. 102-110
Author(s):  
Debra A. Kendall ◽  
Jonathan Choiniere
Keyword(s):  
Cannabinoid Receptor ◽  
Therapeutic Potential ◽  
Allosteric Modulation ◽  
Cannabinoid Receptor 1

The cannabinoid receptor 1 gene (CNR1) and multiple sclerosis: an association study in two case-control groups from Spain

2009 ◽  
Vol 16 (2) ◽  
pp. 139-146 ◽  
Author(s):  
E. Ramil ◽  
AJ Sánchez ◽  
P. González-Pérez ◽  
A. Rodríguez-Antigüedad ◽  
N. Gómez-Lozano ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Cannabinoid Receptor ◽  
Endocannabinoid System ◽  
Case Control ◽  
Genotype Distribution ◽  
Cannabinoid Receptor 1 ◽  
Control Groups ◽  
Gene Encoding ◽  
Significant Difference ◽  
Cnr1 Gene

Different studies point to the implication of the endocannabinoid system in multiple sclerosis (MS) and animal models of MS. The purpose of this study was to evaluate a possible association of MS with polymorphic markers at the CNR1 gene, encoding the cannabinoid 1 (CB1) receptor. We have performed a genetic analysis of an AAT repeat microsatellite localized in the downstream region of the CNR1 gene, in two case—control groups of MS patients and healthy controls (HC) from Spain (Madrid and Bilbao). MS patients with primary progressive MS (PPMS) had more commonly long ((AAT) ≥13) alleles and genotypes with a significant difference for genotype 7/8 in Madrid (p = 0.043) and in the sum of both groups (p = 0.016); short alleles were less frequently found in PPMS with a significant difference for allele 5 in the analysis of both groups together (p = 0.039). In patients with relapsing MS, no consistent differences in allele and genotype distribution were found. Disease severity and progression was unrelated to AAT repeat variations. In conclusion, long (AAT) ≥13 CNR1 genotypes could behave as risk factors for PPMS.

Dual Specificity, Tyrosine phosphorylation Regulated Kinases (DYRKs) in human disease: the therapeutic potential of pharmacological inhibitors

Planta Medica ◽  
2008 ◽  
Vol 74 (09) ◽  
Author(s):  
O Lozach ◽  
Y Ferandin ◽  
B Baratte ◽  
F Le Sourd ◽  
L Meijer
Keyword(s):  
Tyrosine Phosphorylation ◽  
Human Disease ◽  
Therapeutic Potential ◽  
Dual Specificity

Falcarinol (Panaxynol) is a CB1 cannabinoid receptor antagonist and induces pro-allergic effects in skin

Planta Medica ◽  
2009 ◽  
Vol 75 (09) ◽  
Author(s):  
J Gertsch ◽  
M Leonti ◽  
L Casu ◽  
F Cottiglia ◽  
S Raduner ◽  
...  
Keyword(s):  
Receptor Antagonist ◽  
Cannabinoid Receptor ◽  
Cb1 Cannabinoid Receptor

Search for cannabinoid receptor 1 antagonists using structure-based virtual screening: identification of natural product hits

Planta Medica ◽  
2014 ◽  
Vol 80 (10) ◽  
Author(s):  
P Pandey ◽  
KK Roy ◽  
H Liu ◽  
KM Elokely ◽  
S Pettaway ◽  
...  
Keyword(s):  
Virtual Screening ◽  
Natural Product ◽  
Cannabinoid Receptor ◽  
Cannabinoid Receptor 1

Cell-based Tolerogenic Therapy, Experience from Animal Models of Multiple Sclerosis, Type 1 Diabetes and Rheumatoid Arthritis

2017 ◽  
Vol 23 (18) ◽  
Author(s):  
Ivana Stojanovic ◽  
Mirjana Dimitrijevic ◽  
Marta Vives-Pi ◽  
Maria Jose Mansilla ◽  
Irma Pujol-Autonell ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Multiple Sclerosis ◽  
Type 1 Diabetes ◽  
Animal Models

Therapeutic Potential of Amniotic Fluid Derived Mesenchymal Stem Cells Based on their Differentiation Capacity and Immunomodulatory Properties

2019 ◽  
Vol 14 (4) ◽  
pp. 327-336 ◽  
Author(s):  
Carl R. Harrell ◽  
Marina Gazdic ◽  
Crissy Fellabaum ◽  
Nemanja Jovicic ◽  
Valentin Djonov ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Animal Models ◽  
Amniotic Fluid ◽  
Therapeutic Potential ◽  
Inflammatory Diseases ◽  
Therapeutic Effects ◽  
Differentiation Potential ◽  
Differentiation Capacity ◽  
Cell Based Therapy

Background: Amniotic Fluid Derived Mesenchymal Stem Cells (AF-MSCs) are adult, fibroblast- like, self-renewable, multipotent stem cells. During the last decade, the therapeutic potential of AF-MSCs, based on their huge differentiation capacity and immunomodulatory characteristics, has been extensively explored in animal models of degenerative and inflammatory diseases. Objective: In order to describe molecular mechanisms responsible for the therapeutic effects of AFMSCs, we summarized current knowledge about phenotype, differentiation potential and immunosuppressive properties of AF-MSCs. Methods: An extensive literature review was carried out in March 2018 across several databases (MEDLINE, EMBASE, Google Scholar), from 1990 to present. Keywords used in the selection were: “amniotic fluid derived mesenchymal stem cells”, “cell-therapy”, “degenerative diseases”, “inflammatory diseases”, “regeneration”, “immunosuppression”. Studies that emphasized molecular and cellular mechanisms responsible for AF-MSC-based therapy were analyzed in this review. Results: AF-MSCs have huge differentiation and immunosuppressive potential. AF-MSCs are capable of generating cells of mesodermal origin (chondrocytes, osteocytes and adipocytes), neural cells, hepatocytes, alveolar epithelial cells, insulin-producing cells, cardiomyocytes and germ cells. AF-MSCs, in juxtacrine or paracrine manner, regulate proliferation, activation and effector function of immune cells. Due to their huge differentiation capacity and immunosuppressive characteristic, transplantation of AFMSCs showed beneficent effects in animal models of degenerative and inflammatory diseases of nervous, respiratory, urogenital, cardiovascular and gastrointestinal system. Conclusion: Considering the fact that amniotic fluid is obtained through routine prenatal diagnosis, with minimal invasive procedure and without ethical concerns, AF-MSCs represents a valuable source for cell-based therapy of organ-specific or systemic degenerative and inflammatory diseases.

Sign in / Sign up

Export Citation Format

Share Document